Indices of cellular and humoral immunity in a patient with a history of central precocious puberty in anamnesis
- Authors: Khisamutdinova D.R.1, Kozlova Y.I.1, Bashnina E.B.1, Frolova E.V.1, Uchevatkina A.E.1, Filippova L.V.1, Vasilyeva N.V.1
-
Affiliations:
- I. Mechnikov North-Western State Medical University
- Issue: Vol 26, No 4 (2023)
- Pages: 553-558
- Section: Forum Sochi 2023
- URL: https://journal-vniispk.ru/1028-7221/article/view/253441
- DOI: https://doi.org/10.46235/1028-7221-13906-IOC
- ID: 253441
Cite item
Full Text
Abstract
The etiology of precocious puberty includes organic anomalies, genetic mutations, but the primary cause remains unclear in the vast majority of cases. Gonadotropin-releasing hormone (GRH) agonists are used as a treatment of gonadotropin-dependent precocious puberty. Blocking the secretion of gonadotropin-releasing hormone, these drugs stop the premature development of sexual features, prevent premature closure of ossification zones, thereby increasing the child’s expected adult height. The interest in the effects of this group of drugs beyond the hypothalamic-pituitary-gonadal axis has been recently increased. A series of clinical cases have been reported on the development of autoimmune diseases, e.g., autoimmune thyroiditis, Graves disease and type 1 diabetes. The article presents a clinical observation of a patient with central form of premature development who exhibited satisfactory response to treatment with a GRH agonist drug. Further follow-up did not show any reproductive dysfunction. Upon immunological examination, a disturbance was revealed only in the cellular component of immunity. An increased metabolic activity of neutrophils was found, thus, probably, indicating a nonspecific inflammatory process. The levels of immunoglobulins A, M, G matched the reference values. Thus, the therapy with a drug from the group of GRH agonists was effective and safe in terms of influencing the patient’s immune system. The role of hormonal disorders and effects of GRH agonists on the development of immunopathological conditions require further research.
Full Text
##article.viewOnOriginalSite##About the authors
Diliara R. Khisamutdinova
I. Mechnikov North-Western State Medical University
Email: dilyara001@gmail.com
Postgraduate Student, Department of Clinical Mycology, Allergology and Immunology, I. Mechnikov North-Western State Medical University
Russian Federation, St. PetersburgYa. I. Kozlova
I. Mechnikov North-Western State Medical University
Email: kozlova510@mail.ru
ORCID iD: 0000-0002-4602-2438
SPIN-code: 5842-6039
PhD (Medicine), Associate Professor, Department of Clinical Mycology, Allergology and Immunology, I. Mechnikov North-Western State Medical University
Russian Federation, St. PetersburgE. B. Bashnina
I. Mechnikov North-Western State Medical University
Author for correspondence.
Email: bashnina@mail.ru
ORCID iD: 0000-0002-7063-1161
PhD, MD (Medicine), Professor, V. Baranov Department of Endocrinology, I. Mechnikov North-Western State Medical University
Russian Federation, St. PetersburgE. V. Frolova
I. Mechnikov North-Western State Medical University
Email: ekaterina.frolova@szgmu.ru
ORCID iD: 0000-0002-7696-2236
SPIN-code: 9904-8776
PhD (Medicine), Head, Laboratory of Immunology and Allergology, I. Mechnikov North-Western State Medical University
Russian Federation, St. PetersburgA. E. Uchevatkina
I. Mechnikov North-Western State Medical University
Email: a.uchevatkina@szgmu.ru
ORCID iD: 0000-0001-6688-7781
SPIN-code: 3001-4022
PhD (Medicine), Senior Research Associate, Laboratory of Immunology and Allergology, I. Mechnikov North-Western State Medical University
Russian Federation, St. PetersburgL. V. Filippova
I. Mechnikov North-Western State Medical University
Email: larisa.filippova@szgmu.ru
ORCID iD: 0000-0003-4167-7440
SPIN-code: 6810-0871
PhD (Medicine), Senior Research Associate, Laboratory of Immunology and Allergology, I. Mechnikov North-Western State Medical University
Russian Federation, St. PetersburgN. V. Vasilyeva
I. Mechnikov North-Western State Medical University
Email: mycobiota@szgmu.ru
ORCID iD: 0000-0003-3693-5468
SPIN-code: 3929-4370
PhD, MD (Biology), Professor, Director of P. Kashkin Research Institute of Medical Mycology, I. Mechnikov North-Western State Medical University
Russian Federation, St. PetersburgReferences
- Петеркова В.А., Алимова И.Л., Башнина Е.Б., Безлепкина О.Б., Болотова Н.В., Зубкова Н.А., Калинченко Н.Ю., Карева М.А., Кияев А.В., Колодкина А.А., Кострова И.Б., Маказан Н.В., Малиевский О.А., Орлова Е.М., Петряйкина Е.Е., Самсонова Л.Н., Таранушенко Т.Е. Клинические рекомендации «Преждевременное половое развитие» // Проблемы эндокринологии, 2021. Т. 67, № 5. С. 84-103. [Peterkova V.A., Alimova I.L., Bashnina E.B., Bezlepkina O.B., Bolotova N.V., Zubkova N.A., Kalinchenko N.Yu., Kareva M.A., Kiyaev A.V., Kolodkina A.A., Kostrova I.B., Makazan N.V., Malievsky O.A., Orlova E.M., Petryaykina E.E., Samsonova L.N., Taranushenko T.E. Clinical guidelines “ Precocious puberty”. Problemy endokrinologii = Problems of Endocrinology, 2021, Vol. 67, no. 5, pp. 84-103. (In Russ.)]
- Amino N., Hidaka Y., Takano T., Tatsumi K., Izumi Y., Nakata Y. Possible induction of Graves’ disease and painless thyroiditis by gonadotropin-releasing hormone analogues. Thyroid, 2003, Vol. 13, no. 8, pp. 815-818.
- Berntorp K., Frid A., Alm R., Fredrikson G.N., Sjöberg K., Ohlsson B. Antibodies against gonadotropin-releasing hormone (GnRH) in patients with diabetes mellitus is associated with lower body weight and autonomic neuropathy. BMC Res. Notes, 2013, Vol. 6, no. 1, 329. doi: 10.1186/1756-0500-6-329.
- Eyal O., Rose S.R. Autoimmune thyroiditis during leuprolide acetate treatment. J. Pediatr., 2004, Vol. 144, no. 3, pp. 394-396.
- Krstevska-Konstantinova M., Jancevska A., Gucev Z. Autoimune thyroiditis and diabetes mellitus type 1 after long-term gonadotropin-releasing hormone agonist treatment for central precocious puberty: evolution or coincidence? J. Pediatr. Endocrinol. Metab., 2010, Vol. 23, no. 4, pp. 403-406.
- Metcalfe W., Boulton-Jones J.M. Exacerbation of lupus nephritis in association with leuprorelin injection for uterine leiomyoma. Nephrol. Dial. Transplant., 1997, Vol. 12, no. 8, pp. 1699-1700.
- Naderi F., Soheilirad Z., Haghshenas Z. The influence of gonadotropin-releasing hormone agonist treatment on thyroid function tests in children with central idiopathic precocious puberty. Med. Arch., 2019, Vol. 73, no. 2, pp. 101-103.
- Rakab A., Motawea K.R., Rozan S., Mahmoud Hamouda H., Alibrahim H., Elsayed Talat N., Elhalag R., Sawaf B., Mohamed G., Albozom A., Swed S., Mohamed Abuelsaoud H., Mohamed Elshazly R., Hafez W. Association between diabetes and immunoglobulin M antibodies against endogenous gonadotropin-releasing hormone in serum: a meta-analysis. Cureus, 2022, Vol. 14, no. 11, e31415. doi: 10.7759/cureus.31415.
- Wang L., Wu J., Cao H., Chen R., Zhang N., Fu J., Gao B., Zhang J., Hou R., Tang C., Ji Q. The correlation between intestinal gonadotropin-releasing hormone (GnRH) and proglucagon in hyperlipidemic rats and goto-kakizaki (GK) rats. Endocr. Pathol., 2009, Vol. 20, no. 4, pp. 227-234.
- Wang X., Zhong L., Liu Q., Cai P., Zhang P., Lu Z., Li X., Liu J. Activation of gonadotropin-releasing hormone receptor impedes the immunosuppressive activity of decidual regulatory T cells via deactivating the mechanistic target of rapamycin signaling. Immunol Invest., 2022, Vol. 51, no. 5, pp. 1330-1346.
- Zakharova L., Sharova V., Izvolskaia M. Mechanisms of reciprocal regulation of gonadotropin-releasing hormone (gnrh)-producing and immune systems: the role of GnRH, cytokines and their receptors in early ontogenesis in normal and pathological conditions. Int. J. Mol. Sci., 2020, Vol. 22, no. 1, 114. doi: 10.3390/ijms22010114.
Supplementary files
